How have TCF shares performed this year?

Theracryf's stock was trading at GBX 0.65 at the beginning of 2024. Since then, TCF shares have increased by 7.7% and is now trading at GBX 0.70. View the best growth stocks for 2024 here .

How do I buy shares of Theracryf?

Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:TCF

Theracryf (TCF) Share Price, News & Analysis

GBX 0.70

0.00 (0.00%)

(As of 09/5/2024 09:20 PM ET)

Compare

Today's Range: 0.65
▼
0.71
50-Day Range: 0.59
▼
0.90
52-Week Range: 0.59
▼
1.05

Volume: 35,144 shs
Average Volume: N/A
Market Capitalization: £2.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors

Get Theracryf alerts:

Ad Golden Crest

Biden's Successor: The Radical Threat to YOUR Savings!

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

About Theracryf

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy. The company has a partnership with Stalicla to collaborate on a clinical program in autism spectrum disorder. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

TCF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive TCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theracryf and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: Banking
Current Symbol: LON:TCF
CUSIP: N/A
CIK: N/A
Web: theracryf.com
Phone: 44-1625-315-090
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £-3,140,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -81.67%
Return on Assets: -48.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.19
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: GBX 1 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 427,350,000
Free Float: N/A
Market Cap: £2.99 million
Optionable: N/A
Beta: 1.43

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Huw Jones BSc (Age 65)
Ph.D., CEO & Executive Director
Comp: $304.73k
Mr. Toni Haenninen (Age 47)
CFO & Director
Dr. Helen Kuhlman Ph.D.
Chief Business Officer
Dr. Glen Clack FFPM
M.D., Chief Medical Officer

Key Competitors

View All Competitors

TCF Stock Analysis - Frequently Asked Questions

How have TCF shares performed this year?: Theracryf's stock was trading at GBX 0.65 at the beginning of 2024. Since then, TCF shares have increased by 7.7% and is now trading at GBX 0.70.
View the best growth stocks for 2024 here.
How do I buy shares of Theracryf?: Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.